Tecentriq Hybreza (atezolizumab/ hyaluronidase-tqjs)

Adult Dosing .

Dosage forms:  INJ

New FDA Approval: September 2024

[drug not yet available for prescribing; anticipated availability unknown]

Info: atezolizumab binds to PD-L1 on tumor cells and tumor-infiltrating immune cells, blocking PD-1/PD-L1 pathway-mediated inhibition of anti-tumor immune response, resulting in decreased tumor growth; hyaluronidase incr. subcutaneous tissue permeability by temporarily depolymerizing hyaluronan, leading to incr. absorption of atezolizumab

non-small cell lung CA

[content coming soon after drug available for prescribing]

small cell lung CA, extensive-stage

[content coming soon after drug available for prescribing]

hepatocellular CA, unresectable or metastatic

[content coming soon after drug available for prescribing]

melanoma, unresectable or metastatic

[content coming soon after drug available for prescribing]

alveolar soft part sarcoma, unresectable or metastatic

[content coming soon after drug available for prescribing]

Peds Dosing .

Dosage forms:  --

New FDA Approval: September 2024

[Peds dosing is not applicable for this drug]